ArticleCurrent fungal infection reports2026
Updates on Chromoblastomycosis: Evolving Insights in Clinical Management and Therapeutic Strategies.
Article in Current fungal infection reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Predominance of Fonsecaea nubica in Chromoblastomycosis: A Single-Centre Study from Southern India.Mycopathologia · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Purpose of Review: The aim of this review is to provide an in-depth overview of chromoblastomycosis, with emphasis on emerging management strategies and therapeutic options, and to underscore potential gaps in the literature and priorities for future research. Recent Findings: Among the newer triazoles, posaconazole has demonstrated greatest therapeutic potential in the treatment of chromoblastomycosis, including for severe and refractory disease. Adjunctive immunomodulatory therapies such as glucan, imiquimod, and acitretin have shown potential as well. Several novel and repurposed agents also have potential activity against dematiaceous fungi, including tricyclazole, HIV peptidase inhibitors, 1,10-phenanthroline-5,6-dione, and benzimidazoles. A recently proposed combination protocol with debulking, intralesional amphotericin B, and oral terbinafine (DAT protocol) achieved cure in all 16 included patients in a 2025 case series. While excisional surgery remains the preferred physical therapeutic modality, several reports have shown favorable results with both photodynamic and heat therapy. Summary: Chromoblastomycosis continues to pose a therapeutic challenge, requiring prolonged antifungal therapy often combined with physical therapeutic modalities. Improved access to diagnostics and early intervention remain essential to reducing global disease burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.